Project Grant HT94252310807
- The Defense Health Agency awarded a $640,000 Project Grant under the Military Medical Research and Development program (CFDA 12.420) to The Cleveland Clinic Foundation, a non-profit academic medical center, to conduct research focused on "Evolutionary Experimentation Highlights Novel Therapeutic Vulnerabilities in Endometrial Cancer." The award duration is from September 1, 2024 to August 31, 2026. The Cleveland Clinic Foundation, which has extensive experience as both a prime...
- This federal Project Grant award in the amount of $4,503,963 was made by the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420). The award supports a research project titled "Spatial Reprogramming of Tumor Immune Microenvironments by Preoperative Radiotherapy and Immune Checkpoint Inhibition in HER2 Negative Breast Cancer." The project is being led by the University of North Carolina at Chapel Hill (UNC-CH) through its Office of Sponsored...
- The University of Pittsburgh was awarded a $954,000 Project Grant from the Defense Health Agency under the Military Medical Research and Development federal grant program (CFDA 12.420). The grant will support research from May 2023 to May 2026 aimed at epigenetic reprogramming to target senescent ovarian cancer cells and overcome therapeutic resistance. The Military Medical Research and Development program supports basic, applied, and advanced biomedical research to transform military and public...
- This Project Grant award, titled "OVERCOMING IMMUNOTHERAPY RESISTANCE IN ACRAL MELANOMA", is provided by the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420). The $1,183,560 award to the University of Pittsburgh will support advanced biomedical research aimed at transforming healthcare for military service members, veterans, and the broader public. The research project, running from September 1, 2025 to August 31, 2028, will focus on...
- This Project Grant award from the Defense Health Agency's Military Medical Research and Development program (CFDA 12.420) is supporting research at the University of Texas MD Anderson Cancer Center to investigate a novel therapeutic strategy for overcoming immunotherapy resistance in clear cell renal cell carcinoma (cCRCC). The $817,496 award, effective from September 1, 2025 to August 31, 2028, is focused on targeting the PRMT3-IGF2BP1 axis to understand epitranscriptomic reprogramming and...
- This $1,264,474 federal Project Grant award from the Defense Health Agency's Military Medical Research and Development program (CFDA 12.420) supports the University of Pittsburgh's research on "Molecular Insights into Immune Suppression in Kidney Cancer and Novel Therapeutic Opportunities". The grant, effective September 1, 2024 through August 31, 2028, will fund the university's investigations into improving understanding of immune system mechanisms involved in kidney cancer and...
- This $697,590 federal Project Grant award from the Defense Health Agency (CFDA 12.420 - Military Medical Research and Development program) supports research at the H. Lee Moffitt Cancer Center and Research Institute Hospital, Inc. (Moffitt Cancer Center) to evaluate B-T cell cross-talk within tertiary lymphoid structures in melanoma progression and immune checkpoint blockade. The grant, with a performance period from July 1, 2024 to June 30, 2027, aims to advance scientific understanding of...
- This federal Project Grant award in the amount of $1,605,638.00 was provided by the Defense Health Agency (DHA) under the Military Medical Research and Development program (CFDA 12.420). The grant was awarded to The Trustees of the University of Pennsylvania, doing business as the Clinical Practices of the University of Pennsylvania, a private research university and academic medical center. The grant funding supports research aimed at developing new methods for immune targeting of dormant tumor...
- This $1,529,953 federal Project Grant award from the Defense Health Agency under the Military Medical Research and Development (CFDA 12.420) program supports research at the University of Miami to understand the genomic landscape of endometrial cancer in Black women. The project aims to advance scientific understanding of this disease and its impact on a population that is disproportionately affected. The research will be conducted by the University of Miami's Office of Research Administration -...
- This federal Project Grant award, provided by the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research), supports research to define the mechanisms by which immune checkpoint inhibitor-associated bacteria modulate tumor immunity in cancer, particularly melanoma. The University of Pittsburgh will receive $636,222 over the award period of April 1, 2025 to March 31, 2030. The key focus of this research is to understand how microbial-derived aryl hydrocarbon receptor (AhR) ligands...
This federal Project Grant award of $613,793.00 from the Defense Health Agency's Military Medical Research and Development program (CFDA 12.420) supports research on immunosuppressive factors contributing to immunotherapy resistance in endometrial cancer with deficient mismatch repair. The primary awardee, Magee-Womens Research Institute and Foundation, will be responsible for the overall project, which involves extensive immune monitoring and profiling of tumor and blood samples from a clinical trial on checkpoint inhibitor therapy for endometrial cancer. The research aims to define the role of immunosuppressive factors like CCL2-mediated TAM recruitment and CD47/TGF-β signaling in modulating the tumor immune microenvironment. It will also evaluate whether targeting these pathways can enhance response to PD-1/PD-L1 blockade in preclinical models. The project involves two sub-awards to support the translational research components. The Cleveland Clinic Foundation will conduct immunological analyses of clinical trial samples, while the University of Pittsburgh will process samples and perform data analysis to correlate immune signatures with treatment outcomes. This multi-institutional collaboration leverages the expertise and research capabilities of these leading academic medical centers.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $613.8k | 7/20/23 |
GrantNumber | Description | Subgrantee | Prime Award | Dollars Obligated | Updated At |
|---|---|---|---|---|---|
PITT2714AMD1S | University Of Pittsburgh - Of The Commonwealth System Of Higher Education | Project Grant HT94252310807 | $100.1k | 3/17/25 | |
CLEVELAND2714AMD1S | The Cleveland Clinic Foundation | Project Grant HT94252310807 | $59.8k | 10/16/24 | |
CLEVELANDORG2714S | The Cleveland Clinic Foundation | Project Grant HT94252310807 | $29.9k | 11/15/23 | |
PITTORG2714S | University Of Pittsburgh - Of The Commonwealth System Of Higher Education | Project Grant HT94252310807 | $60.6k | 9/23/23 |